Eintrag weiter verarbeiten
M1 Stage Subdivision and Treatment Outcome of Patients With Bone-Only Metastasis of Nasopharyngeal Carcinoma
Gespeichert in:
| Zeitschriftentitel: | The Oncologist |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , |
| In: | The Oncologist, 20, 2015, 3, S. 291-298 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Oxford University Press (OUP)
|
| Schlagwörter: |
| Zusammenfassung: | <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background.</jats:title> <jats:p>The current M1 stage in nasopharyngeal carcinoma (NPC) does not differentiate patients based on metastatic site and number of metastases. This study aims to subdivide the M1 stage of NPC patients with bone-only metastases and to identify the patients who may benefit from combined chemoradiotherapy (CRT).</jats:p> </jats:sec> <jats:sec> <jats:title>Methods.</jats:title> <jats:p>Between 1998 and 2007, 312 patients diagnosed with bone-only metastasis at Sun Yat-sen University Cancer Center were enrolled. Various possible subdivisions of M1 stage were considered, including by the time order of metastasis (synchronous vs. metachronous), involvement of specific bone metastatic site, the number of metastatic sites, and the number of metastases. The correlation of the subdivisions of M1 stage with overall survival (OS) was determined by Cox regression.</jats:p> </jats:sec> <jats:sec> <jats:title>Results.</jats:title> <jats:p>The median OS was 23.4 months. Patients with more than three metastatic sites had significantly poorer OS than patients with three or fewer metastatic sites (16.2 vs. 32.4 months; p &lt; .001). Metastasis to the spine was significantly associated with unfavorable OS (20.4 vs. 37.9 months; p &lt; .001). Multivariate analysis showed that number of metastatic sites (more than three vs. three or fewer), spine involvement (present vs. absent), and treatment modality (CRT vs. chemotherapy or radiotherapy only) were independent prognostic factors for OS. In stratified analysis, compared with chemotherapy or radiotherapy alone, combined chemoradiotherapy could significantly benefit the patients with single bone metastasis (hazard ratio: 0.21; 95% confidence interval: 0.09–0.50).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion.</jats:title> <jats:p>Metastasis to the spine and having more than three bone metastatic sites are independent unfavorable predictors for OS in NPC patients with bone-only metastasis. Combined chemoradiotherapy should be considered for patients with single bone metastasis.</jats:p> </jats:sec> |
|---|---|
| Umfang: | 291-298 |
| ISSN: |
1083-7159
1549-490X |
| DOI: | 10.1634/theoncologist.2014-0206 |